Micro-x Ltd. · ASX:MX1
Micro-x — Non-Deal Roadshow (July 2025)
24 slides from Micro-x's roadshow presentation, Jul 30, 2025
Slide 1: Company Presentation - Investor non-deal roadshow and Bioshares Conference
COMPANY PRESENTATION Investor non-deal roadshow meetings and 19th Bioshares Conference Adelaide, Australia, 30 July 2025: Australian hi-tech company Micro-X Ltd (ASX:MX1) (Micro-X or the Company), a leader in cold cathode X-ray technology for health and security markets globally, advises that Compan
Slide 2: Investor Presentation: Commercial execution
For personal use only INVESTOR PRESENTATION C om me rcia l e xe cu tion K in gs le y Hal l Ch ie f E xe c uti ve O f fi ce r 3 0 Jul y 2 02 5 Micro-X Investor Presentation I 1
Slide 3: Important Notice
IMPORTANT NOTICE S C O P E & L I M I T A T I O N S For personal use only This Presentation has been prepared by Micro-X Limited (Micro-X or the Company) (ASX.MX1). The Presentation is a summary only and does not contain all the information about the Company’s assets and liabilities, financial positi
Slide 4: Creating revolutionary X-ray imaging to better lives
For personal use only CREATING REVOLUTIONARY X -RAY IMAGING TO BETTER LIVES C u riou s I C oll ab or ativ e I D e term in ed Micro-X Investor Presentation I 3
Slide 5: Overview
OVERVI EW Growing commercial momentum with Next Generation X-ray technology For personal use only 1 Rover Plus sales momentum – Supply contract with major US healthcare provider 2 Building our X-ray & CT portfolio – focused on commercial execution – Unique features of proprietary NEX Technology 3 He
Slide 6: World first imaging technology
WOR LD FI RST IMAGI NG TECHNOLOGY Proprietary NEX Technology redefines portability and precision for X-ray innovation For personal use only Micro-X imaging solution – X-ray Tubes – Generators – HV Connectors – Software Micro-X Investor Presentation I 5
Slide 7: Medical imaging portfolio
M E D I C A L I M A G I N G P O R TF O L I O Pioneering smaller, smarter X-ray and CT through patented technology platform For personal use only R OVE R P L US HEA D CT FUL L BODY CT - MO BILE DIG IT AL R ADIOGR APH Y - MO BILE ST RO KE DET ECTION - POR TA BL E IMAG IN G SO LUTIO N Ultra-mobile x-ra
Slide 8: Strategies & priorities
S T R A TE G I E S & P R I O R I TI E S Three key near term objectives focus to drive execution with a focus on tangible outcomes For personal use only 01 02 03 Deliver large Commence Monetise Rover Plus Sales Head CT imaging trials Security Division – Major healthcare operator supply agreement - Pa
Slide 9: Validation & partners
VAL IDATI ON & PAR TNER S Non dilutive funding to de-risk development and unlock value For personal use only $29m funding $25m funding $8m funding Development Checkpoints & Baggage Full Body CT Head CT Partners Scanner – U.S. Airports – Stroke Diagnosis – Portable & Lightweight >$80m partnership fun
Slide 10: Experienced leadership
EXPER IENCED L EADERSHIP Commercially focused to accelerate growth For personal use only Kingsley Hall – CEO Brian Gonzales, PhD – CEO Americas Patrick O'Brien , Non-Exec Chair Jim McDowell, Non-Exec 25+ years exp in senior operational and Recognised industry leader in x-ray physics, CNT Former Seni
Slide 11: Medical imaging portfolio
For personal use only MEDICAL IMAGING PORTFOLIO L e v e r a g i n g w o r l d - l e a d i n g N E X T e c h n o l o g y Micro-X Investor Presentation I 10
Slide 12: Rover Plus - growing sales
R O VE R P L U S – G R O W I N G S A L E S First mobile imaging product – validates tube & generator technology For personal use only Growing Recent Contract win - Major US Healthcare Group Margins → Supply Contract with Major US Healthcare Group – after two stage in hospital evaluation → Additional
Slide 13: Micro-X CT - technology evolution
MICR O-X CT - TECHNOLOGY EVOLUTI ON Over 375 million CT images annually1,2 For personal use only NEX Technology – major advantages over traditional CT SIMPLER COST EFFECTIVE No rotating slip ring / No cooling Cheaper to build and install Simple, reliable CNT tubes Cheaper to maintain & operate SM AL
Slide 14: Head CT - prototype near ready for trials
H E A D C T – P R O T O T Y P E N E A R R E A D Y F O R TR I A L S Hospital and ambulance imaging trials to support regulatory approvals and launch in 2027 For personal use only $8.0m ASA funding contract World first - Successful 3D CT clinical images → Micro-X proprietary mini tubes and generator w
Slide 15: Full Body CT - portable solution
F U L L B O D Y C T – P O R T A B L E S O L U TI O N Extension of current Micro-X Technology – bringing CT scanning to the patient For personal use only $25m ARPA-H funding contract ARPA-H awards $25m development funding contract → Initial funding of $12.5M for first 2 years - up to $25M for a total
Slide 16: Security offerings
For personal use only SECURITY OFFERINGS M o n e t i s i n g S e c u r i t y - S t r a t e g i c P a r t n e r s h i p s Micro-X Investor Presentation I 15
Slide 17: Monetising security business
M O N E TI S I N G S E C U R I T Y B U S I N E S S Realising value from fully funded development work with US Department of Homeland Security For personal use only $29m Partnerships to monetise technology & take to market DHS funding → Discussions ongoing to sell complete baggage scanner design / se
Slide 18: Baggage & parcel scanner - partnership
B AGGAGE & P AR CEL S CAN NER – P AR TNER SH IP $5.6m deal with Billion Prima - Malaysian high-tech scanning specialist For personal use only $5.6m partnership Partnership to develop a baggage scanner for SE ASIA → Billion Prima are a specialist in baggage and cargo scanning technology in Malaysia →
Slide 19: Driving commercial success
For personal use only DRIVING COMMERCIAL SUCCESS B u i l d i n g a b u s i n e s s , n o t j u s t a t e c h n o l o g y Micro-X Investor Presentation I 18
Slide 20: Commercial timeline
COMMER CIAL TIMELI NE Commercialising a portfolio of products Products Funding / Status 2025 2026 2027 For personal use only Approved / Revenue Execute larger Cashflow positive Further growth ~400 units sold to date sales opportunities operations 3D Images - Prototype Human imaging Regulatory Approv
Slide 21: Ethical & sustainable corporate growth
ETH ICAL & SU STA INA BL E CORP ORA TE GROWTH Environmental, Social and Governance credentials ENVIRONMENT PEOPLE GOVERNANCE For personal use only 24% 25% ZERO Female employees Female board US FDA, EU MDR, Environmental incidents 16 nationalities Veterans ARTG Employment represented Commitment Devel
Slide 22: Corporate & financials
COR POR ATE Retail and HNW Institutional /Strategic 42.5% & F INA NCI AL S 55.2% For personal use only Board & Management 2.3% FINANCIALS & SHAREHOLDERS SHARE CAPITAL (28 July 2025) $17.9m Contracted Payments FY26 onwards Cash ~$5.1m (31 Mar 2025) Share price $0.065 per share Revenue $4.0m (1H FY25)
Slide 23: Wrap up
WRAP UP A clear path forward For personal use only 1 Commercial & customer focus is delivering results 2 Rover Plus sales momentum – building towards breakeven 3 Stroke imaging about to commence trials 4 Near term opportunity to monetise security business 5 Validated by strong partners – funding & a
Slide 24: For more information
For personal use only For more information visit: www.micro-x.com Micro-X Limited Investor Enquiries Kingsley Hall, Chief Executive Officer David Allen / John Granger Rebecca Puddy, Head of Corporate Hawkesbury Partners Communications Tel: +61 410 577 155 Tel: +61 8 7099 3966 Tel: +61 499 100 038 Em